PatientsVille.com Logo

ABNORMAL BEHAVIOUR and Naproxen

PatientsVille

ABNORMAL BEHAVIOUR Symptoms and Causes

Alcohol can harm your baby at any stage during a pregnancy. That includes the earliest stages, before you even know you are pregnant. Drinking during pregnancy can cause a group of conditions called fetal alcohol spectrum disorders (FASDs). Children who are born with FASD can have a mix of problems, such as medical, behavioral, educational, and social problems. The kinds of problems they have depend on which type of FASD they have. The problems could include

  • Abnormal facial features, such as a smooth ridge between the nose and upper lip
  • Small head size
  • Shorter-than-average height
  • Low body weight
  • Poor coordination
  • Hyperactive behavior
  • Difficulty with attention and memory
  • Learning disabilities and difficulty in school
  • Speech and language delays
  • Intellectual disability or low IQ
  • Poor reasoning and judgment skills
  • Sleep and sucking problems as a baby
  • Vision or hearing problems
  • Problems with the heart, kidneys, or bones

Fetal alcohol syndrome (FAS) is the most serious type of FASD. People with fetal alcohol syndrome have facial abnormalities, including wide-set and narrow eyes, growth problems and nervous system abnormalities.

Diagnosing FASD can be hard because there is no medical test for it. The health care provider will make a diagnosis by looking at the child's signs and symptoms, and will ask whether the mother drank alcohol during pregnancy.

FASDs last a lifetime. There is no cure for FASDs, but treatments can help. These include medicines to help with some symptoms, medical care for health problems, behavior and education therapy, and parent training. A good treatment plan is specific to the child's problems. It should include close monitoring, follow-ups, and changes when needed.

Certain "protective factors" can help reduce the effects of FASDs and help people who have them reach their full potential. They include

  • Diagnosis before 6 years of age
  • Loving, nurturing, and stable home environment during the school years
  • Absence of violence around them
  • Involvement in special education and social services

There is no known safe amount of alcohol during pregnancy. To prevent FASDs, you should not drink alcohol while you are pregnant, or when you might get pregnant.

Centers for Disease Control and Prevention

Check out the latest treatments for ABNORMAL BEHAVIOUR

ABNORMAL BEHAVIOUR treatment research studies

Naproxen clinical trials, surveys and public health registries


Find Drug Side Effect reports



Naproxen Side Effects

Nausea (230)
Gastrointestinal Haemorrhage (220)
Pain (205)
Renal Failure Acute (198)
Dyspnoea (188)
Haemoglobin Decreased (171)
Completed Suicide (169)
Vomiting (162)
Dizziness (158)
Diarrhoea (155)
Gastric Ulcer (153)
Abdominal Pain (149)
Haematemesis (145)
Gastric Haemorrhage (137)
Chest Pain (123)
Duodenal Ulcer (122)
Abdominal Pain Upper (118)
Pruritus (118)
Anaemia (109)
Arthralgia (104)
Asthenia (65)
Pulmonary Embolism (64)
Rash (63)
No Adverse Event (63)
Melaena (63)
Upper Gastrointestinal Haemorrhage (62)
Headache (62)
Malaise (61)
Oedema Peripheral (58)
Deep Vein Thrombosis (58)
Urticaria (57)
Hypersensitivity (56)
Toxicity To Various Agents (56)
Anxiety (55)
Pyrexia (53)
Fatigue (50)
Faeces Discoloured (50)
Back Pain (49)
Cardiac Arrest (49)
Pain In Extremity (47)
Cholelithiasis (46)
Hypotension (45)
Overdose (44)
Injury (44)
Swelling Face (43)
Gastritis (42)
Feeling Abnormal (42)
Angioedema (42)
Depression (41)
Blood Creatinine Increased (39)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I had a leg pain and my doctor prescribe naproxen for me. After I took the medicine for two days I felt the dizziness and back pain. The back pain cause me sleepless and burning arm.

I took 2tablets of naproxen on wednesday and he next day i noticed twitching in mt face arms and legs i also started getting sores on the inside of my mouth it is now saturday and imstill experiencing the twitching and w

I was on 1000mg a day for months (then self medicated to 500mg) and developed difficulty breathing and trouble getting to sleep. My health professionals repeatedly didn't link it to naproxen. Recently i experienced tingling sensations in my hands and

I was prscribed Naproxen 500Mg tab to take twice daily. The morning of the 3rd day my upper lip was swollen twice the size, I also had sores inside my lip. I was not sure what the cause was until the fourth day, after researching

Increased blood glucose

Nose bleeds

Reddening of cheeks

SsSWOLLEN EYELIDS .BAGS UNDER EYES.BACK OF EYES WERE VERY PAINFUL,AND STILL ARE.FELT VERY ILL.

Swollen feet and ankle.

This stuff got my upper gi burning like its on fire wht the hell should i do

after taking my medicine .i felt abnormal taste in mouth and my bilurubin level was increased.

After one week on my new medicationfeeling aggressive paranoid and anxious, went from feeling on top of my world to now feeling really 'shitty'This isunusual behaviour for me, I am a professional woman running my own pra

I took centrum for almost one month.and I notice that my menstruation suddenly became abnormal in cycle..in short AMENNORHEA....until now iam almost 1 month and 3 days delayed and took pregnancy test but the result was

<strong>I took 2 capsules at 7.20m after having breakfast and started feeling side effects at 8.25am. It started with increased temperature, abnormal levels of perspiration, dizziness and severe nausea. </strong

1100 sinus rhythm 2210 short pr intrval 9150 abnormal**ecg

9150 **abnormal ecg

Abnormal dreams!!!!

Abnormal ear wax after usage and healing from Ciprodex.

After 2 and half months of taking boniva i devoped severe shoulder pain that cause tendonitis and bursitis and abnormal bone formation and will have to have surgery now to inprove my pain i have been in severe pain for 5 months now boniva side eff

After taking Stilnox I had trouble to control my behaviour, and just as my boyfriend told me I've been walking naked around our neighbourhood ( one out of ton of other things), I realized I must stop taking it. But, since I have such a big trouble sl

ABNORMAL BEHAVIOUR Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
Condition: Precancerous Condition
Interventions: Drug: Naproxen;   Other: placebo;   Other: laboratory biomarker analysis
Outcome Measures: Change in PGE2 concentration levels in normal colorectal mucosa;   Minimal biologically effective dose of Naproxen defined by modulation of PGE2 levels;   Response defined as >= 30% reduction in PGE2 levels;   Incidence of toxicity graded according to National Cancer Institute Common Criteria for Adverse Events (NCI CTCAE) version 4.0;   Naproxen concentrations in plasma samples;   Naproxen concentrations in normal colorectal mucosa;   PGE-M levels in urine samples;   Change in number of polyps observed in the rectosigmoid area;   Changes in the microRNA profile of the normal colorectal mucosa;   Changes in gene expression mRNA profiles of the normal colorectal mucosa;   Changes in the mutational rate of the normal colorectal mucosa
2 Unknown  Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee
Condition: Osteoarthritis, Knee
Interventions: Drug: Naproxen;   Drug: Placebo
Outcome Measures: Efficacy of Naproxen vs. placebo;   Safety
3 Not yet recruiting Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
Conditions: Migraine;   Headache
Interventions: Drug: naratriptan + Naproxen;   Drug: naratriptan;   Drug: Naproxen
Outcome Measures: Headache relief 2 hours after dosing, without use of rescue medication;   Headache relief 4 hours after dosing, without use of rescue medication;   Maintenance of pain relief between 2 and 24 hours after dosing, without use of rescue medication;   Pain-free response 2 and 4 hours after dosing, without use of rescue medication;   Maintenance of pain-free response between 2 and 24 hours, without use of rescue medication;   Freedom from nausea, vomiting, photophobia and phonophobia 2 and 4 hours after dosing;   Maintenance of freedom from nausea, vomiting, photophobia and phonophobia between 2 and 24 hours after dosing, without use of rescue medication;   Recurrence of pain between 2 and 24 hours after dosing, without use of rescue medication;   Proportion of subjects who used rescue medication between 2 and 24 hours after dosing, at least once;   Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
4 Unknown  Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
Conditions: Migraine;   Headache
Interventions: Drug: Fixed-dose combination of naratriptan + Naproxen;   Drug: Naratriptan;   Drug: Naproxen
Outcome Measures: Headache relief 2 hours after dosing, without use of rescue medication.;   Headache relief 4 hours after dosing, without use of rescue medication;   Sustained headache relief over 24 hours, without use of rescue medication;   Pain-free response 2 and 4 hours after dosing, without use of rescue medication;   Sustained pain-free response over 24 hours, without use of rescue medication;   Freedom from photophobia, phonophobia and nausea 2 and 4 hours after dosing, without use of rescue medication;   Sustained freedom from photophobia, phonophobia and nausea from 2 through 24 hours after dosing, without use of rescue medication;   Proportion of subjects who used rescue medication between 2 and 24 hours after dosing, at least once;   Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
5 Recruiting Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients
Conditions: Arthritis;   Cardiovascular Diseases;   Cerebrovascular Disorders
Interventions: Drug: Celecoxib(drug);   Drug: Naproxen(drug)
Outcome Measures: Recurrent ulcer bleeding within 78 weeks according to pre-specified criteria;   Cardiovascular events
6 Recruiting NOLAN: Naproxen or Loratadine and Neulasta
Condition: Bone Pain in Stage I - III Breast Cancer
Interventions: Drug: Naproxen;   Drug: Loratadine
Outcome Measures: Bone pain (all grade) in cycle 1;   Bone pain (all grade) by cycle (2-4) and across cycles;   Severe (grade 3/4) bone pain by cycle and across cycles;   Subject reported bone pain;   Maximum Subject Reported bone pain;   Area under the Curve for subject-reported bone pain;   Adverse Event and Serious Adverse Events;   Severity of Adverse Events
7 Unknown  Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial
Condition: Pain, Postoperative
Interventions: Drug: Naproxen;   Drug: placebo
Outcome Measures: cumulative opiate dose administered, as recorded on the computerized medication administration record (CMAR);   patient reported pain scores;   side effects of study medication and opiate analgesia
8 Recruiting The Effect of Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection
Conditions: Pleural Effusion;   Pleural Effusion Malignant
Interventions: Drug: Naproxen;   Drug: Placebo
Outcome Measures: Change in volume of pleural effusion collected;   Hospital length of stay; compared between intervention and control arms;   Gastrointestinal complications;   General re-admission rates;   Total number of days chest tubes remain in-situ
9 Recruiting Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
Condition: Arthritis, Rheumatoid
Interventions: Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Outcome Measures: The first occurrence of cardiovascular death (including hemorrhagic death), non-fatal myocardial infarction, or non-fatal stroke (APTC composite endpoint).;   The occurrence of Clinical Significant Gastrointestinal Events (CSGIEs);   Patient's Assessment of Arthritis Pain (VAS);   The first occurrence of a MACE defined as the composite of cardiovascular death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA
10 Not yet recruiting Effect of L-dopa In Subacute Back Pain Population
Condition: Sub-acute Back Pain
Interventions: Drug: Naproxen;   Drug: Carbidopa/Levodopa;   Drug: Placebo
Outcome Measure: VAS pain scale
11 Not yet recruiting Colchicine Or Naproxen Treatment for ACute gouT
Condition: Gout
Interventions: Drug: Low-dose colchicine;   Drug: Naproxen
Outcome Measure: Change in pain intensity
12 Not yet recruiting Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects
Condition: Acute Pain
Interventions: Drug: Naproxen;   Drug: Sinemet;   Drug: Placebo
Outcome Measure: VAS pain scale
13 Recruiting Efficacy of Sumatriptan With Naprosyn in Migraine With Aura
Condition: Migraine With Aura
Interventions: Drug: sumatriptan with naprosyn;   Drug: placebo
Outcome Measures: Primary outcome measure will be comparative percentage of patients pain free at 2 and 4 hours from initiating treatment with placebo vs treatment with Treximet (sumatriptan with naprosyn).;   Secondary outcomes will be percentage of patients with pain relief at 2 and 4 hours.
14 Recruiting A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
Condition: Juvenile Idiopathic Arthritis (JIA)
Interventions: Drug: VIMOVO 250/20;   Drug: VIMOVO 375/20;   Drug: VIMOVO 500/20
Outcome Measures: Incidence of severity of AEs and SAEs.;   Change in serum iron/total iron binding capacity (serum iron/TIBC), Vitamin B12, and magnesium.;   Change from baseline in vital signs, physical examination results and clinical laboratory tests.;   Pharmacokinetic (PK) in terms of characteristics of VIMOVO (Naproxen / esomeprazole).
15 Not yet recruiting Placebo In Chronic Pain
Condition: Chronic Back Pain
Interventions: Drug: Naproxen;   Drug: Placebo;   Drug: Omeprazole
Outcome Measure: VAS pain scale
16 Recruiting Low Level Laser Therapy Versus Pharmacotherapy in in Improving Masticatory Muscle Pain
Condition: TMD
Interventions: Radiation: low level laser therapy;   Drug: Naproxen
Outcome Measure: reduction of paim measured by VAS
17 Recruiting Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment
Condition: Back Pain
Interventions: Drug: Ketorolac Tromethamine;   Drug: Naproxen
Outcome Measures: Efficacy of treatment in back pain relief based on Visual Analog Scale (VAS).;   Safety will be evaluated by the adverse events occurrences
18 Not yet recruiting Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment
Condition: Back Pain
Interventions: Drug: Ketorolac Tromethamine;   Drug: Naproxen
Outcome Measures: Efficacy of treatment in back pain relief based on Visual Analogic Score (VAS).;   Safety will be evaluated by the adverse events occurrences
19 Recruiting A Randomized Study of Three Medication Regimens for Acute Low Back Pain
Condition: Acute Low Back Pain
Interventions: Drug: Naproxen;   Drug: Cyclobenzaprine;   Drug: Oxycodone/ acetaminophen
Outcome Measure: Roland Morris low back pain functional disability scale
20 Unknown  Ictal and Interictal Inflammatory Markers in Migraine
Condition: Migraine
Interventions: Drug: sumatriptan/Naproxen sodium;   Drug: Placebo
Outcome Measure: Blood levels of proteins will be evaluated at baseline when subjects are pain-free and then repeated during an acute attack, both prior to drug administration and then at 30 minutes, 1 hour and 2 hours after acute treatment.